Aurinia Historical Cash Flow

AUPH Stock  USD 8.98  0.03  0.34%   
Analysis of Aurinia Pharmaceuticals cash flow over time is an excellent tool to project Aurinia Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 4.7 M or Depreciation of 12.2 M as it is a great indicator of Aurinia Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Aurinia Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aurinia Pharmaceuticals is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.

About Aurinia Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Aurinia balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Aurinia's non-liquid assets can be easily converted into cash.

Aurinia Pharmaceuticals Cash Flow Chart

As of now, Aurinia Pharmaceuticals' Sale Purchase Of Stock is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Change To Netincome is estimated to increase to about 39.6 M, while Change In Cash is forecasted to increase to (43 M).

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Change In Working Capital

The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Aurinia Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Aurinia Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.
Most accounts from Aurinia Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Aurinia Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.As of now, Aurinia Pharmaceuticals' Sale Purchase Of Stock is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Change To Netincome is estimated to increase to about 39.6 M, while Change In Cash is forecasted to increase to (43 M).

Aurinia Pharmaceuticals cash flow statement Correlations

0.170.44-0.36-0.280.21-0.20.040.340.140.00.38-0.070.270.09-0.15-0.11-0.480.540.560.560.55
0.170.73-0.88-0.09-0.59-0.360.95-0.760.17-0.640.66-0.020.620.35-0.71-0.46-0.510.20.580.690.56
0.440.73-0.48-0.32-0.180.10.62-0.190.07-0.380.240.070.50.7-0.590.08-0.580.340.770.810.75
-0.36-0.88-0.480.070.550.63-0.850.75-0.230.6-0.840.09-0.6-0.080.610.670.51-0.29-0.48-0.55-0.47
-0.28-0.09-0.320.07-0.520.02-0.26-0.05-0.470.620.080.02-0.54-0.340.660.220.86-0.83-0.69-0.49-0.7
0.21-0.59-0.180.55-0.520.48-0.480.670.220.1-0.57-0.04-0.250.230.030.35-0.20.450.14-0.030.15
-0.2-0.360.10.630.020.48-0.340.5-0.190.31-0.860.06-0.650.630.220.880.22-0.06-0.01-0.02-0.01
0.040.950.62-0.85-0.26-0.48-0.34-0.840.24-0.820.57-0.050.620.37-0.84-0.53-0.620.340.620.670.61
0.34-0.76-0.190.75-0.050.670.5-0.84-0.160.65-0.570.04-0.45-0.030.560.620.230.04-0.13-0.19-0.12
0.140.170.07-0.23-0.470.22-0.190.24-0.16-0.350.130.390.290.17-0.37-0.25-0.420.370.220.110.23
0.0-0.64-0.380.60.620.10.31-0.820.65-0.35-0.410.0-0.61-0.270.950.60.82-0.67-0.7-0.64-0.7
0.380.660.24-0.840.08-0.57-0.860.57-0.570.13-0.41-0.010.63-0.36-0.39-0.8-0.320.130.270.360.26
-0.07-0.020.070.090.02-0.040.06-0.050.040.390.0-0.01-0.060.120.050.160.06-0.06-0.07-0.06-0.07
0.270.620.5-0.6-0.54-0.25-0.650.62-0.450.29-0.610.63-0.06-0.04-0.66-0.68-0.690.360.550.470.55
0.090.350.7-0.08-0.340.230.630.37-0.030.17-0.27-0.360.12-0.04-0.440.5-0.380.310.530.520.52
-0.15-0.71-0.590.610.660.030.22-0.840.56-0.370.95-0.390.05-0.66-0.440.480.87-0.7-0.83-0.77-0.82
-0.11-0.460.080.670.220.350.88-0.530.62-0.250.6-0.80.16-0.680.50.480.44-0.29-0.23-0.21-0.23
-0.48-0.51-0.580.510.86-0.20.22-0.620.23-0.420.82-0.320.06-0.69-0.380.870.44-0.9-0.92-0.81-0.91
0.540.20.34-0.29-0.830.45-0.060.340.040.37-0.670.13-0.060.360.31-0.7-0.29-0.90.830.710.84
0.560.580.77-0.48-0.690.14-0.010.62-0.130.22-0.70.27-0.070.550.53-0.83-0.23-0.920.830.960.99
0.560.690.81-0.55-0.49-0.03-0.020.67-0.190.11-0.640.36-0.060.470.52-0.77-0.21-0.810.710.960.92
0.550.560.75-0.47-0.70.15-0.010.61-0.120.23-0.70.26-0.070.550.52-0.82-0.23-0.910.840.990.92
Click cells to compare fundamentals

Aurinia Pharmaceuticals Account Relationship Matchups

Aurinia Pharmaceuticals cash flow statement Accounts

201920202021202220232024 (projected)
Change In Cash188.1M(33.7M)(40.5M)(137.7M)(45.3M)(43.0M)
Free Cash Flow(63.6M)(77.2M)(159.2M)(79.8M)(34.2M)(35.9M)
Change In Working Capital2.1M4.5M(21.6M)(6.8M)(5.6M)(5.3M)
Begin Period Cash Flow118.0M306.0M272.4M231.9M94.2M62.0M
Other Cashflows From Financing Activities20.7M6.6M24.4M2.4M4.9M4.7M
Depreciation1.5M1.4M2.8M2.7M11.6M12.2M
Other Non Cash Items8.2M9.5M10.9M462K(6.8M)(6.5M)
Capital Expenditures104K7.3M1.5M292K718K1.0M
Total Cash From Operating Activities(63.5M)(69.9M)(157.7M)(79.5M)(33.5M)(35.1M)
Net Income(123.8M)(102.7M)(181.0M)(108.2M)(78.0M)(74.1M)
Total Cash From Financing Activities243.7M194.4M221.1M2.4M(5.1M)(4.9M)
End Period Cash Flow306.0M272.4M231.9M94.2M48.9M63.8M
Sale Purchase Of Stock4.0M243.9M194.4M221.1M254.3M267.0M
Investments7.8M(150.8M)(84.5M)(60.6M)(3.5M)(3.6M)
Total Cashflows From Investing Activities7.8M(158.2M)(103.9M)(60.6M)(54.6M)(51.8M)
Change To Account Receivables(151K)(13.6M)(15.4M)1.9M(10.6M)(10.1M)
Change To Operating Activities(2.0M)4.8M(4.7M)(3.4M)(3.1M)(2.9M)
Change To Netincome21.6M20.1M42.1M32.8M37.7M39.6M
Change To Liabilities4.0M13.6M4.1M3.7M4.3M4.5M
Stock Based Compensation7.4M17.5M31.2M32.3M45.3M47.6M

Currently Active Assets on Macroaxis

When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.15)
Revenue Per Share
1.536
Quarterly Revenue Growth
0.243
Return On Assets
(0.02)
Return On Equity
(0.06)
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.